Related Experiment Video
Updated: May 2, 2026
04:41
Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
Published on: July 14, 2010
22.4K
Betaine suppressed Aβ generation by altering amyloid precursor protein processing
Xiu-Ping Liu1, Xiang Qian, Yue Xie
1Department of Clinical Laboratory, Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou, 310007, China, 470299188@qq.com.
Summary
Betaine, a choline metabolite, may protect against Alzheimer's disease (AD) by reducing amyloid-beta (Aβ) production. This study shows Betaine alters amyloid precursor protein (APP) processing, decreasing Aβ levels.
Area of Science:
- Neuroscience
- Biochemistry
- Pharmacology
Background:
- Betaine is an endogenous choline metabolite found in plants and seafood.
- Clinically, betaine is used for hyperlipidemia, coronary atherosclerosis, and fatty liver.
- Emerging evidence links betaine to mitigating homocysteine-induced neuronal damage and Alzheimer's disease (AD) pathology.
Purpose of the Study:
- To investigate betaine's effect on amyloid-beta (Aβ) production.
- To explore the mechanism by which betaine influences amyloid precursor protein (APP) processing.
Main Methods:
- Utilized N2a cells engineered to express a Swedish mutant of APP.
- Assessed the impact of betaine on APP secretase activities (α-secretase and β-secretase).
Main Results:
- Betaine treatment led to a reduction in Aβ levels in the studied cell model.
- Betaine was found to enhance α-secretase activity.
- Betaine was observed to decrease β-secretase activity.
Conclusions:
- Betaine may offer neuroprotection by modulating APP processing pathways.
- The findings suggest betaine's potential therapeutic role in reducing Aβ production, a key factor in AD pathogenesis.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:29Drugs Affecting Neurotransmitter Synthesis
2.5K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.5K
03:03Amyloid Fibrils
10.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
10.2K